These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 30859374)

  • 1. Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Garrett M; Ruiz-Garcia A; Parivar K; Hee B; Boni J
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):211-222. PubMed ID: 30859374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059.
    Wu JH; Pennesi E; Bautista F; Garrett M; Fukuhara K; Brivio E; Ammerlaan ACJ; Locatelli F; van der Sluis IM; Rossig C; Chen-Santel C; Bielorai B; Petit A; Starý J; Díaz-de-Heredia C; Rives S; O'Marcaigh A; Rizzari C; Engstler G; Nysom K; Rubio-San-Simón A; Bruno B; Bertrand Y; Brethon B; Rialland F; Plat G; Dirksen U; Sramkova L; Zwaan CM; Huitema ADR
    Clin Pharmacokinet; 2024 Jul; 63(7):981-997. PubMed ID: 38907948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
    Fayad L; Offner F; Smith MR; Verhoef G; Johnson P; Kaufman JL; Rohatiner A; Advani A; Foran J; Hess G; Coiffier B; Czuczman M; Giné E; Durrant S; Kneissl M; Luu KT; Hua SY; Boni J; Vandendries E; Dang NH
    J Clin Oncol; 2013 Feb; 31(5):573-83. PubMed ID: 23295790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
    Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling.
    Hibma JE; Kantarjian HM; DeAngelo DJ; Boni JP
    Br J Clin Pharmacol; 2019 Mar; 85(3):590-600. PubMed ID: 30536405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: A Report of Four Cases.
    Okura M; Ida N; Yamauchi T
    Intern Med; 2020 Aug; 59(16):2047-2051. PubMed ID: 32389945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
    Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
    Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
    Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
    N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.
    Kantarjian HM; Su Y; Jabbour EJ; Bhattacharyya H; Yan E; Cappelleri JC; Marks DI
    Cancer; 2018 May; 124(10):2151-2160. PubMed ID: 29508899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
    Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
    Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
    Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment.
    Marks DI; van Oostrum I; Mueller S; Welch V; Vandendries E; Loberiza FR; Böhme S; Su Y; Stelljes M; Kantarjian HM
    Cancer Med; 2019 Oct; 8(13):5959-5968. PubMed ID: 31436395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system.
    Lee TY; Chen HY; Chen TY; Li SS; Fang WT; Wen YC; Lo YW; Ou HT
    Eur J Health Econ; 2020 Sep; 21(7):1105-1116. PubMed ID: 32506280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
    Wynne J; Wright D; Stock W
    Blood Adv; 2019 Jan; 3(1):96-104. PubMed ID: 30622147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
    Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
    Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
    Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
    Dahl J; Marx K; Jabbour E
    Expert Rev Hematol; 2016; 9(4):329-34. PubMed ID: 26783163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
    Jain N; O'Brien S; Thomas D; Kantarjian H
    Front Biosci (Elite Ed); 2014 Jan; 6(1):40-5. PubMed ID: 24389139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.
    Li X; Zhou M; Qi J; Han Y
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e227-e247. PubMed ID: 33461955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.